FibroBiologics, Inc.
FBLG
$0.35
$0.025.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,055.60% | -618.71% | 41.30% | 68.11% | 77.19% |
| Total Depreciation and Amortization | 61.54% | 47.14% | 17.52% | 17.69% | 27.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.80% | 109.34% | -70.10% | -98.02% | -604.58% |
| Change in Net Operating Assets | 231.82% | -203.46% | -471.12% | -187.74% | -108.73% |
| Cash from Operations | -52.42% | -104.62% | -23.39% | -91.94% | -128.80% |
| Capital Expenditure | 45.45% | -222.73% | -437.50% | -4,850.00% | 97.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 45.45% | -222.73% | -437.50% | -4,850.00% | 97.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 2,643.60% | -- | -- | 375.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -314.56% | 108.15% | -429.15% | 484.15% | 402.94% |